iX Biopharma

The amount surpasses the goal of S$5 million; new shares issued at S$0.10 apiece

The placement price represents a discount of 9.7% to the volume weighted average price of S$0.1107 per share

This brings the counter up 408% in the year to date

PHARMACEUTICAL company iX Biopharma posted an S$8.3 million loss for the second half of the fiscal year ended June 2022, sinking deeper into the red from a S$5.4 million loss in H2 FY2021.

CATALIST-LISTED iX Biopharma has swung back into the black with a net profit of S$3.7 million for the first half of its fiscal year ended Dec 31, 2021, compared with a net loss of S$2.8 million the pr...

CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics - a clinical-stage biopharmaceutical company.

PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) for the licensing, supply and distribu...

PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with CRPCG for the licensing, supply and distribution of Wafesil, a sublingual sildenafil wafer for th...

After the planned HK listing of its pharmaceutical and medical cannabis business, the company will focus on nutraceuticals. BY JANICE HENG